Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin SF, Linn SC, Young LS, Jirström K, Crown J, Bernards R, Caldas C, Gallagher WM, O'Connor DP, Ni Chonghaile T.

Clin Cancer Res. 2019 Aug 13. pii: clincanres.0713.2019. doi: 10.1158/1078-0432.CCR-19-0713. [Epub ahead of print]

PMID:
31409615
2.

Altered steroid milieu in AI resistant breast cancer facilitates AR mediated gene expression associated with poor response to therapy.

Creevey L, Bleach R, Madden SF, Toomey S, Bane FT, Varešlija D, Hill AD, Young LS, McIlroy M.

Mol Cancer Ther. 2019 Jul 9. pii: molcanther.0791.2018. doi: 10.1158/1535-7163.MCT-18-0791. [Epub ahead of print]

PMID:
31289138
3.

Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers.

Lindner AU, Lucantoni F, Varešlija D, Resler A, Murphy BM, Gallagher WM, Hill ADK, Young LS, Prehn JHM.

J Mol Med (Berl). 2018 Oct;96(10):1025-1037. doi: 10.1007/s00109-018-1675-0. Epub 2018 Aug 1.

PMID:
30069746
4.

Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.

Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O'Halloran PJ, Ward E, Cocchiglia S, Hartmaier R, Castro CA, Zhu L, Tseng GC, Lucas PC, Puhalla SL, Brufsky AM, Hamilton RL, Mathew A, Leone JP, Basudan A, Hudson L, Dwyer R, Das S, O'Connor DP, Buckley PG, Farrell M, Hill ADK, Oesterreich S, Lee AV, Young LS.

J Natl Cancer Inst. 2019 Apr 1;111(4):388-398. doi: 10.1093/jnci/djy110.

5.

Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.

Ward E, Varešlija D, Charmsaz S, Fagan A, Browne AL, Cosgrove N, Cocchiglia S, Purcell SP, Hudson L, Das S, O'Connor D, O'Halloran PJ, Sims AH, Hill AD, Young LS.

Clin Cancer Res. 2018 Aug 1;24(15):3692-3703. doi: 10.1158/1078-0432.CCR-17-2615. Epub 2018 Mar 22.

6.

Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.

Browne AL, Charmsaz S, Varešlija D, Fagan A, Cosgrove N, Cocchiglia S, Purcell S, Ward E, Bane F, Hudson L, Hill AD, Carroll JS, Redmond AM, Young LS.

Oncogene. 2018 Apr;37(15):2008-2021. doi: 10.1038/s41388-017-0042-x. Epub 2018 Jan 25.

7.

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.

Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV.

JAMA Oncol. 2017 May 1;3(5):666-671. doi: 10.1001/jamaoncol.2016.5630. Erratum in: JAMA Oncol. 2017 Mar 1;3(3):418.

8.

Patient-Derived Xenografts of Breast Cancer.

Varešlija D, Cocchiglia S, Byrne C, Young L.

Methods Mol Biol. 2017;1501:327-336.

PMID:
27796962
9.

Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.

Varešlija D, McBryan J, Fagan A, Redmond AM, Hao Y, Sims AH, Turnbull A, Dixon JM, Ó Gaora P, Hudson L, Purcell S, Hill AD, Young LS.

Clin Cancer Res. 2016 Jun 1;22(11):2765-77. doi: 10.1158/1078-0432.CCR-15-1583. Epub 2016 Jan 13.

10.

Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy.

McBryan J, Fagan A, McCartan D, Bane FT, Varešlija D, Cocchiglia S, Byrne C, Bolger J, McIlroy M, Hudson L, Tibbitts P, Gaora PÓ, Hill AD, Young LS.

Clin Cancer Res. 2015 Dec 1;21(23):5371-9. doi: 10.1158/1078-0432.CCR-14-2155. Epub 2015 Aug 3.

11.

AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.

O'Hara J, Vareslija D, McBryan J, Bane F, Tibbitts P, Byrne C, Conroy RM, Hao Y, Gaora PÓ, Hill AD, McIlroy M, Young LS.

Clin Cancer Res. 2012 Jun 15;18(12):3305-15. doi: 10.1158/1078-0432.CCR-11-3300. Epub 2012 May 1.

12.

Highly reactive oxygen species: detection, formation, and possible functions.

Freinbichler W, Colivicchi MA, Stefanini C, Bianchi L, Ballini C, Misini B, Weinberger P, Linert W, Varešlija D, Tipton KF, Della Corte L.

Cell Mol Life Sci. 2011 Jun;68(12):2067-79. doi: 10.1007/s00018-011-0682-x. Epub 2011 May 2. Review.

PMID:
21533983

Supplemental Content

Loading ...
Support Center